Mepolizumab Market Report 2026

The mepolizumab market size has grown strongly in recent years. It will grow from $2.22 billion in 2025 to $2.38 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising prevalence of severe asthma, increasing awareness of eosinophilic disorders, growth in biologics research and development, expansion of specialty care services, improved diagnostic capabilities for inflammatory diseases.

The mepolizumab market size is expected to see strong growth in the next few years. It will grow to $3.21 billion by 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, expansion of biologics pipeline, growing demand for home-based treatment options, advancements in targeted immunotherapies, rising healthcare investments in chronic disease management. Major trends in the forecast period include increasing adoption of monoclonal antibody therapies, growing use of biologics for severe asthma management, rising demand for steroid-sparing treatment options, expanding clinical applications in eosinophilic disorders, improved patient adherence through targeted therapies.

The increasing global burden of asthma is anticipated to propel the growth of the mepolizumab market coming years. The increasing global burden of asthma is anticipated to propel the growth of the mepolizumab market coming years. Asthma refers to a chronic respiratory condition in which the airways (bronchi) become inflamed, narrow, and produce excess mucus, making it difficult to breathe. The rise of asthma is due to people being exposed to a combination of genetic and environmental factors, which can trigger inflammation in the airways of the body and make the lungs more sensitive, which leads to a higher prevalence of asthma. Mepolizumab helps asthma by allowing the reduction of inflammation caused by eosinophils, which are a type of white blood cell that contributes to airway swelling and asthma attacks. For instance, in February 2026, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based independent statutory agency, asthma contributes 2.5% to Australia’s total disease burden in 2024, is the leading cause of disease burden among children aged 1-9, drives approximately $1.3 billion in healthcare spending in 2023-24, and shows higher prevalence and hospitalization rates in boys compared to girls. Furthermore, in February 2023, according to NHS England, a UK-based executive non-departmental public body, approximately 5.4 million individuals are undergoing asthma treatment, with around 160,000 new diagnoses occurring annually, and occupational exposure contributing to nearly 9-15% of adult-onset asthma cases. Therefore, the increasing global burden of asthma is driving the growth of the mepolizumab market.

Leading companies operating in the mepolizumab market are focusing on developing innovative products, such as eosinophil-targeting biologics to expand therapeutic indications and improve disease management outcomes. An eosinophil-targeting biologic is a monoclonal antibody therapy that inhibits interleukin-5 to reduce eosinophil-mediated inflammation. For example, in January 2026, GlaxoSmithKline PLC, a UK-based biopharmaceutical company, announced China’s National Medical Products Administration (NMPA) approval of Nucala (mepolizumab). The therapy demonstrates statistically significant reductions in moderate to severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease when added to standard inhaled treatments. Its approval introduces a targeted biologic option in a large patient population, supporting improved clinical outcomes and reducing hospitalization burden.

The growing adoption of biologic treatments is anticipated to drive the growth of the mepolizumab market coming years. The growing adoption of biologic treatments is anticipated to drive the growth of the mepolizumab market coming years. Biologic treatments are advanced therapeutic agents derived from living organisms or their components, designed to target specific molecular pathways involved in disease pathogenesis, particularly in immune-mediated and inflammatory conditions. A key factor driving the growing adoption of biologic treatments is their ability to deliver highly targeted mechanisms of action, which enables improved clinical outcomes with reduced off-target effects compared to conventional therapies, thereby increasing physician confidence and patient preference for precision-based interventions. Mepolizumab selectively inhibits interleukin-5, demonstrating the clinical value of biologic treatments in effectively managing eosinophilic conditions and reinforcing their adoption in respiratory care. For instance, in August 2023, according to the British Generic Manufacturers Association, a UK-based trade association, forecasts from the Office of Health Economics indicate that National Health Service biosimilar sales are expected to reach approximately $33 billion (£26 billion) over the period from 2023 to 2028. Therefore, the growing adoption of biologic treatments is driving the growth of the mepolizumab market.

Major companies operating in the mepolizumab market are GlaxoSmithKline plc, Bio‑Thera Solutions Ltd.

North America was the dominating region in the mepolizumab market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the mepolizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mepolizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mepolizumab market consists of sales of products such as lyophilized powder for reconstitution into a subcutaneous injection, a prefilled syringe for subcutaneous administration, and a single-use autoinjector designed for subcutaneous delivery. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.